Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Clin Cancer Res. 2022 May 2;28(9):1863–1870. doi: 10.1158/1078-0432.CCR-21-3018

Figure 2: Molecular landscape of the discovery cohort.

Figure 2:

A) Comparison of the genetic landscape of RNF43-mut, RSPOfp and RNF43/RSPOfp-WT tumors. Shown are mutations that are significantly different between RSPOfp vs. RNF43-mut tumors (all q<0.05; ns: p<0.05, but q<0.05 was not reached).

B) Copy number alterations in RNF43-mut, RSPOfp and RNF43/RSPO-WT tumors. *q<0.05, **q<0.01, ***q<0.001.

C) MSI, TMB and PDL-1 status in RNF43-mut, RSPOfp and RNF43/RSPOfp-WT tumors. None of the RSPOfp patients showed a TMB >10 mt/Mb or a MSI-H/dMMR status.*q<0.05, **q<0.01, ***q<0.001.